Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 national diabetes registries

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes : an international multicentre study based on data from 13 national diabetes registries. / Birkebaek, Niels H.; Kamrath, Clemens; Grimsmann, Julia M.; Aakesson, Karin; Cherubini, Valentino; Dovc, Klemen; de Beaufort, Carine; Alonso, Guy T.; Gregory, John W.; White, Mary; Skrivarhaug, Torild; Sumnik, Zdenek; Jefferies, Craig; Hörtenhuber, Thomas; Haynes, Aveni; De Bock, Martin; Svensson, Jannet; Warner, Justin T.; Gani, Osman; Gesuita, Rosaria; Schiaffini, Riccardo; Hanas, Ragnar; Rewers, Arleta; Eckert, Alexander J.; Holl, Reinhard W.; Cinek, Ondrej.

I: The Lancet Diabetes and Endocrinology, Bind 10, Nr. 11, 2022, s. 786-794.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Birkebaek, NH, Kamrath, C, Grimsmann, JM, Aakesson, K, Cherubini, V, Dovc, K, de Beaufort, C, Alonso, GT, Gregory, JW, White, M, Skrivarhaug, T, Sumnik, Z, Jefferies, C, Hörtenhuber, T, Haynes, A, De Bock, M, Svensson, J, Warner, JT, Gani, O, Gesuita, R, Schiaffini, R, Hanas, R, Rewers, A, Eckert, AJ, Holl, RW & Cinek, O 2022, 'Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 national diabetes registries', The Lancet Diabetes and Endocrinology, bind 10, nr. 11, s. 786-794. https://doi.org/10.1016/S2213-8587(22)00246-7

APA

Birkebaek, N. H., Kamrath, C., Grimsmann, J. M., Aakesson, K., Cherubini, V., Dovc, K., de Beaufort, C., Alonso, G. T., Gregory, J. W., White, M., Skrivarhaug, T., Sumnik, Z., Jefferies, C., Hörtenhuber, T., Haynes, A., De Bock, M., Svensson, J., Warner, J. T., Gani, O., ... Cinek, O. (2022). Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 national diabetes registries. The Lancet Diabetes and Endocrinology, 10(11), 786-794. https://doi.org/10.1016/S2213-8587(22)00246-7

Vancouver

Birkebaek NH, Kamrath C, Grimsmann JM, Aakesson K, Cherubini V, Dovc K o.a. Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 national diabetes registries. The Lancet Diabetes and Endocrinology. 2022;10(11):786-794. https://doi.org/10.1016/S2213-8587(22)00246-7

Author

Birkebaek, Niels H. ; Kamrath, Clemens ; Grimsmann, Julia M. ; Aakesson, Karin ; Cherubini, Valentino ; Dovc, Klemen ; de Beaufort, Carine ; Alonso, Guy T. ; Gregory, John W. ; White, Mary ; Skrivarhaug, Torild ; Sumnik, Zdenek ; Jefferies, Craig ; Hörtenhuber, Thomas ; Haynes, Aveni ; De Bock, Martin ; Svensson, Jannet ; Warner, Justin T. ; Gani, Osman ; Gesuita, Rosaria ; Schiaffini, Riccardo ; Hanas, Ragnar ; Rewers, Arleta ; Eckert, Alexander J. ; Holl, Reinhard W. ; Cinek, Ondrej. / Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes : an international multicentre study based on data from 13 national diabetes registries. I: The Lancet Diabetes and Endocrinology. 2022 ; Bind 10, Nr. 11. s. 786-794.

Bibtex

@article{a88ad71fb0a849c3af747d9fd8abe1d3,
title = "Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 national diabetes registries",
abstract = "Background: An increased prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in children was observed in various diabetes centres worldwide during the COVID-19 pandemic. We aimed to evaluate trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes before and during the COVID-19 pandemic, and to identify potential predictors of changes in diabetic ketoacidosis prevalence during the pandemic. Methods: For this international multicentre study, we used data from 13 national diabetes registries (Australia, Austria, Czechia, Denmark, Germany, Italy, Luxembourg, New Zealand, Norway, Slovenia, Sweden, USA [Colorado], and Wales). The study population comprised 104 290 children and adolescents aged 6 months to younger than 18 years, who were diagnosed with type 1 diabetes between Jan 1, 2006, and Dec 31, 2021. The observed diabetic ketoacidosis prevalence in 2020 and 2021 was compared to predictions based on trends over the pre-pandemic years 2006–19. Associations between changes in diabetic ketoacidosis prevalence and the severity of the COVID-19 pandemic and containment measures were examined with excess all-cause mortality in the whole population and the Stringency Index from the Oxford COVID-19 Government Response Tracker. Findings: 87 228 children and adolescents were diagnosed with type 1 diabetes between 2006 and 2019, 8209 were diagnosed in 2020, and 8853 were diagnosed in 2021. From 2006 to 2019, diabetic ketoacidosis at diagnosis of type 1 diabetes was present in 23 775 (27·3%) of 87 228 individuals and the mean annual increase in the prevalence of diabetic ketoacidosis in the total cohort from 2006 to 2019 was 1·6% (95% CI 1·3 to 1·9). The adjusted observed prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes was 39·4% (95% CI 34·0 to 45·6) in 2020 and 38·9% (33·6 to 45·0) in 2021, significantly higher than the predicted prevalence of 32·5% (27·8 to 37·9) for 2020 and 33·0% (28·3 to 38·5) for 2021 (p<0·0001 for both years). The prevalence of diabetic ketoacidosis was associated with the pandemic containment measures, with an estimated risk ratio of 1·037 (95% CI 1·024 to 1·051; p<0·0001) per ten-unit increase in the Stringency Index for 2020 and 1·028 (1·009 to 1·047; p=0·0033) for 2021, but was not significantly associated with excess all-cause mortality. Interpretation: During the COVID-19 pandemic, there was a marked exacerbation of the pre-existing increase in diabetic ketoacidosis prevalence at diagnosis of type 1 diabetes in children. This finding highlights the need for early and timely diagnosis of type 1 diabetes in children and adolescents. Funding: German Federal Ministry for Education and Research, German Robert Koch Institute, German Diabetes Association, German Diabetes Foundation, Slovenian Research Agency, Welsh Government, Central Denmark Region, and Swedish Association of Local Authorities and Regions.",
author = "Birkebaek, {Niels H.} and Clemens Kamrath and Grimsmann, {Julia M.} and Karin Aakesson and Valentino Cherubini and Klemen Dovc and {de Beaufort}, Carine and Alonso, {Guy T.} and Gregory, {John W.} and Mary White and Torild Skrivarhaug and Zdenek Sumnik and Craig Jefferies and Thomas H{\"o}rtenhuber and Aveni Haynes and {De Bock}, Martin and Jannet Svensson and Warner, {Justin T.} and Osman Gani and Rosaria Gesuita and Riccardo Schiaffini and Ragnar Hanas and Arleta Rewers and Eckert, {Alexander J.} and Holl, {Reinhard W.} and Ondrej Cinek",
note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",
year = "2022",
doi = "10.1016/S2213-8587(22)00246-7",
language = "English",
volume = "10",
pages = "786--794",
journal = "The Lancet Diabetes & Endocrinology",
issn = "2213-8587",
publisher = "The Lancet Publishing Group",
number = "11",

}

RIS

TY - JOUR

T1 - Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes

T2 - an international multicentre study based on data from 13 national diabetes registries

AU - Birkebaek, Niels H.

AU - Kamrath, Clemens

AU - Grimsmann, Julia M.

AU - Aakesson, Karin

AU - Cherubini, Valentino

AU - Dovc, Klemen

AU - de Beaufort, Carine

AU - Alonso, Guy T.

AU - Gregory, John W.

AU - White, Mary

AU - Skrivarhaug, Torild

AU - Sumnik, Zdenek

AU - Jefferies, Craig

AU - Hörtenhuber, Thomas

AU - Haynes, Aveni

AU - De Bock, Martin

AU - Svensson, Jannet

AU - Warner, Justin T.

AU - Gani, Osman

AU - Gesuita, Rosaria

AU - Schiaffini, Riccardo

AU - Hanas, Ragnar

AU - Rewers, Arleta

AU - Eckert, Alexander J.

AU - Holl, Reinhard W.

AU - Cinek, Ondrej

N1 - Publisher Copyright: © 2022 Elsevier Ltd

PY - 2022

Y1 - 2022

N2 - Background: An increased prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in children was observed in various diabetes centres worldwide during the COVID-19 pandemic. We aimed to evaluate trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes before and during the COVID-19 pandemic, and to identify potential predictors of changes in diabetic ketoacidosis prevalence during the pandemic. Methods: For this international multicentre study, we used data from 13 national diabetes registries (Australia, Austria, Czechia, Denmark, Germany, Italy, Luxembourg, New Zealand, Norway, Slovenia, Sweden, USA [Colorado], and Wales). The study population comprised 104 290 children and adolescents aged 6 months to younger than 18 years, who were diagnosed with type 1 diabetes between Jan 1, 2006, and Dec 31, 2021. The observed diabetic ketoacidosis prevalence in 2020 and 2021 was compared to predictions based on trends over the pre-pandemic years 2006–19. Associations between changes in diabetic ketoacidosis prevalence and the severity of the COVID-19 pandemic and containment measures were examined with excess all-cause mortality in the whole population and the Stringency Index from the Oxford COVID-19 Government Response Tracker. Findings: 87 228 children and adolescents were diagnosed with type 1 diabetes between 2006 and 2019, 8209 were diagnosed in 2020, and 8853 were diagnosed in 2021. From 2006 to 2019, diabetic ketoacidosis at diagnosis of type 1 diabetes was present in 23 775 (27·3%) of 87 228 individuals and the mean annual increase in the prevalence of diabetic ketoacidosis in the total cohort from 2006 to 2019 was 1·6% (95% CI 1·3 to 1·9). The adjusted observed prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes was 39·4% (95% CI 34·0 to 45·6) in 2020 and 38·9% (33·6 to 45·0) in 2021, significantly higher than the predicted prevalence of 32·5% (27·8 to 37·9) for 2020 and 33·0% (28·3 to 38·5) for 2021 (p<0·0001 for both years). The prevalence of diabetic ketoacidosis was associated with the pandemic containment measures, with an estimated risk ratio of 1·037 (95% CI 1·024 to 1·051; p<0·0001) per ten-unit increase in the Stringency Index for 2020 and 1·028 (1·009 to 1·047; p=0·0033) for 2021, but was not significantly associated with excess all-cause mortality. Interpretation: During the COVID-19 pandemic, there was a marked exacerbation of the pre-existing increase in diabetic ketoacidosis prevalence at diagnosis of type 1 diabetes in children. This finding highlights the need for early and timely diagnosis of type 1 diabetes in children and adolescents. Funding: German Federal Ministry for Education and Research, German Robert Koch Institute, German Diabetes Association, German Diabetes Foundation, Slovenian Research Agency, Welsh Government, Central Denmark Region, and Swedish Association of Local Authorities and Regions.

AB - Background: An increased prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in children was observed in various diabetes centres worldwide during the COVID-19 pandemic. We aimed to evaluate trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes before and during the COVID-19 pandemic, and to identify potential predictors of changes in diabetic ketoacidosis prevalence during the pandemic. Methods: For this international multicentre study, we used data from 13 national diabetes registries (Australia, Austria, Czechia, Denmark, Germany, Italy, Luxembourg, New Zealand, Norway, Slovenia, Sweden, USA [Colorado], and Wales). The study population comprised 104 290 children and adolescents aged 6 months to younger than 18 years, who were diagnosed with type 1 diabetes between Jan 1, 2006, and Dec 31, 2021. The observed diabetic ketoacidosis prevalence in 2020 and 2021 was compared to predictions based on trends over the pre-pandemic years 2006–19. Associations between changes in diabetic ketoacidosis prevalence and the severity of the COVID-19 pandemic and containment measures were examined with excess all-cause mortality in the whole population and the Stringency Index from the Oxford COVID-19 Government Response Tracker. Findings: 87 228 children and adolescents were diagnosed with type 1 diabetes between 2006 and 2019, 8209 were diagnosed in 2020, and 8853 were diagnosed in 2021. From 2006 to 2019, diabetic ketoacidosis at diagnosis of type 1 diabetes was present in 23 775 (27·3%) of 87 228 individuals and the mean annual increase in the prevalence of diabetic ketoacidosis in the total cohort from 2006 to 2019 was 1·6% (95% CI 1·3 to 1·9). The adjusted observed prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes was 39·4% (95% CI 34·0 to 45·6) in 2020 and 38·9% (33·6 to 45·0) in 2021, significantly higher than the predicted prevalence of 32·5% (27·8 to 37·9) for 2020 and 33·0% (28·3 to 38·5) for 2021 (p<0·0001 for both years). The prevalence of diabetic ketoacidosis was associated with the pandemic containment measures, with an estimated risk ratio of 1·037 (95% CI 1·024 to 1·051; p<0·0001) per ten-unit increase in the Stringency Index for 2020 and 1·028 (1·009 to 1·047; p=0·0033) for 2021, but was not significantly associated with excess all-cause mortality. Interpretation: During the COVID-19 pandemic, there was a marked exacerbation of the pre-existing increase in diabetic ketoacidosis prevalence at diagnosis of type 1 diabetes in children. This finding highlights the need for early and timely diagnosis of type 1 diabetes in children and adolescents. Funding: German Federal Ministry for Education and Research, German Robert Koch Institute, German Diabetes Association, German Diabetes Foundation, Slovenian Research Agency, Welsh Government, Central Denmark Region, and Swedish Association of Local Authorities and Regions.

U2 - 10.1016/S2213-8587(22)00246-7

DO - 10.1016/S2213-8587(22)00246-7

M3 - Journal article

C2 - 36202118

AN - SCOPUS:85140313329

VL - 10

SP - 786

EP - 794

JO - The Lancet Diabetes & Endocrinology

JF - The Lancet Diabetes & Endocrinology

SN - 2213-8587

IS - 11

ER -

ID: 323996526